Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Astellas Pharma Europe Ltd
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 5 ans
PRE-transplant pharmacokinetics and Advagraf® Dosing In kidney transplant ReCipienTs Farmacocinética pre-trasplante y dosis de Advagraf® en receptores de trasplanate renal
The primary objective of the study is to assess if Advagraf® pharmacokinetic parameters measured prior to transplantation can predict the dose required after transplantation to achieve target trough l...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 5 ans
A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4))
The primary objective of this study is to compare the four therapy regimens with regard to efficacy failure rate.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 5 ans
INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS – A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY
To compare the two treatment arms with regard to incidence of new onset diabetes Mellitus as per the American Diabetic Association criteria at any point up to 24 weeks after kidney transplantation. Ar...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 5 ans
Randomized, Open label, Non-inferiority Study of Micafungin versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients
To demonstrate non-inferiority of micafungin at a dose of 100 mg/day versus ‘standard care’ for the prevention of Invasive Fungal Disease, defined according to the revised EORTC/MSG criteria, in ‘high...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 5 ans
A LONG-TERM FOLLOW UP STUDY TO EVALUATE THE SAFETY AND EFFICACY IN TRANSPLANT RECIPIENTS TREATED WITH MODIFIED RELEASE TACROLIMUS, FK506E (MR4); BASED IMMUNOSUPPRESSION REGIMEN
The objective of this study is to assess the safety and efficacy of FK506E (MR4) as long-term treatment in transplant recipients who have participated in one of the phase II PK or phase III studies on...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 5 ans
Comparison of efficacy and safety of Qutenza vs Lyrica
To compare the efficacy of QUTENZA versus pregabalin in subjects with peripheral neuropathic pain (PNP) after 8 weeks
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 5 ans
A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS
Primary objective is to assess the changes in kidney function in kidney transplant subjects converted from a CyA-based immunosuppressive regimen to a tacrolimus modified release, FK506E (MR4), based i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 5 ans
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concomitantly an infection of the gut caused by bacteria called Clostridium difficile
The primary objective of the study is to investigate the plasma pharmacokinetics (PK) of fidaxomicin and primary metabolite OP-1118 in Subjects with Inflammatory Bowel Disease (IBD) and C. difficile I...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 5 ans
Studying kidney function in patients with a kidney transplant treated with anti-rejection therapy based on Advagraf when used with or without sirolimus
To compare the effect two immunosuppressive therapy regimens on Glomerular Filtration Rate (GFR) estimated by Iohexol clearance at Week 52 post kidney transplantation. Arm 1: Advagraf® + MMF + Steroi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe Ltd
MAJ Il y a 5 ans
A study in which two antibiotics (vancomycin and fidaxomicin) are compared in older patients with infections of the gut caused by bacteria called Clostridium difficile
The primary objective of the study is to evaluate whether the extended duration fidaxomicin therapy is superior to the standard vancomycin therapy in sustained clinical cure of CDI at 30 days after en...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
1
2
3
Suivant